


Correction

# Correction: Watanabe et al. Pemaifibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. *Livers* 2023, 3, 562–568

Azuma Watanabe <sup>1,\*</sup>, Ryoko Horigome <sup>1</sup>, Yumiko Nakatsuka <sup>1</sup> and Shuji Terai <sup>2</sup> 

<sup>1</sup> Department of Gastroenterology, Kameda Daiichi Hospital, 2-5-22 Nishimachi, Konan-ku, Niigata City 9500165, Niigata, Japan; hrgm\_ryonryon1127@nifty.com (R.H.); iyumi@ya2.so.ne.jp (Y.N.)

<sup>2</sup> Division of Gastroenterology and Hepatology, Graduate School of Medical and Dental Sciences, Niigata University, 1-754 Asahimachidori, Niigata City 9518520, Niigata, Japan; terais@med.niigata-u.ac.jp

\* Correspondence: azuwata@ijn.or.jp; Tel.: +81-25-382-3111; Fax: +81-25-382-7311

## Error in Table 4

In the original publication [1], there was a mistake in Table 4 (entitled “Changes in clinical parameters before and after pemaifibrate therapy”) as published. The BMI “After” value was incorrect. The corrected Table 4 appears below. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

**Table 4.** Changes in clinical parameters before and after pemaifibrate therapy.

Variables	Before	After	p Value
Weight (kg)	68.3 ± 14.2	68.9 ± 14.1	<0.05
BMI (kg/m <sup>2</sup> )	25.4 ± 4.2	25.7 ± 4.1	<0.05
AST (IU/L)	36.1 ± 32.1	27.8 ± 17.0	0.005
ALT (IU/L)	43.7 ± 43.8	24.0 ± 13.8	<0.001
γ-GPT (IU/L)	93.8 ± 210.2	44.3 ± 129.3	<0.001
Platelet (10 <sup>4</sup> /μL)	24.6 ± 7.2	26.9 ± 8.6	<0.001
M2BPGi	0.9 ± 0.7	0.7 ± 0.5	<0.05
Triglyceride (mg/dL)	234.6 ± 126.3	126.7 ± 68.4	<0.001
HDL-C (mg/dL)	52.6 ± 12.9	55.7 ± 11.6	0.001
LDL-C (mg/dL)	118.4 ± 35.2	111.9 ± 28.0	0.06
Cre (mg/dL)	0.8 ± 0.2	0.8 ± 0.2	0.57
eGFR (mL/min/1.73 m <sup>2</sup> )	73.0 ± 15.2	73.1 ± 15.5	0.70
Glucose (mg/dL)	138.7 ± 42.1	130.4 ± 38.1	0.15
HbA1c (%)	6.5 ± 1.0	6.4 ± 1.0	0.87



Received: 27 January 2025

Accepted: 30 January 2025

Published: 27 February 2025

**Citation:** Watanabe, A.; Horigome, R.; Nakatsuka, Y.; Terai, S. Correction: Watanabe et al. Pemaifibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. *Livers* 2023, 3, 562–568. *Livers* 2025, 5, 10. <https://doi.org/10.3390/livers5010010>

**Copyright:** © 2025 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## Reference

1. Watanabe, A.; Horigome, R.; Nakatsuka, Y.; Terai, S. Pemaifibrate Improves Alanine Aminotransferase Levels Independently of Its Lipid-Lowering Effect. *Livers* 2023, 3, 562–568. [[CrossRef](#)]

**Disclaimer/Publisher’s Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.